CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March

Key Points

• Short interest fell 14.2% in March to 414,235 shares (about 1.2% of shares outstanding), with a days-to-cover of roughly 3.2 based on average daily volume.
• Analyst sentiment is mildly positive: the stock has an average rating of "Moderate Buy" with an average target price of $8.60 (five Buys, one Hold, one Sell), and recent upgrades include Leerink raising its target to $9 and Rodman & Renshaw initiating coverage with a Buy.
• Despite the coverage, CAMP4 reported weak results — EPS of ($0.87) vs. consensus ($0.31), just $0.35M in revenue, a market cap of ~$243M, and deeply negative profitability metrics (negative ROE and net margin), with analysts forecasting ~-4.99 EPS for the year.

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) was the recipient of a large decrease in short interest during the month of March. As of March 31st, there was short interest totaling 414,235 shares, a decrease of 14.2% from the March 15th total of 483,060 shares. Approximately 1.2% of the shares of the stock are sold short. Based on an average daily volume of 128,124 shares, the days-to-cover ratio is currently 3.2 days.

Hedge Funds Weigh In On CAMP4 Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CAMP. Bank of America Corp DE bought a new stake in shares of CAMP4 Therapeutics in the 4th quarter worth approximately $86,000. Bridgeway Capital Management LLC bought a new stake in CAMP4 Therapeutics in the second quarter worth $36,000. Two Sigma Investments LP bought a new stake in CAMP4 Therapeutics in the third quarter worth $292,000. Vivo Capital LLC purchased a new stake in shares of CAMP4 Therapeutics in the third quarter worth $11,765,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of CAMP4 Therapeutics in the 4th quarter worth about $61,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on CAMP. Leerink Partners boosted their price objective on shares of CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an "outperform" rating in a report on Thursday, April 2nd. Weiss Ratings reissued a "sell (e+)" rating on shares of CAMP4 Therapeutics in a research note on Monday, December 29th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of CAMP4 Therapeutics in a research note on Friday, March 6th. Finally, Rodman & Renshaw began coverage on CAMP4 Therapeutics in a report on Tuesday. They issued a "buy" rating and a $7.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $8.60.

CAMP4 Therapeutics Trading Up 2.1%

NASDAQ CAMP traded up $0.10 on Friday, hitting $4.69. The company's stock had a trading volume of 6,117 shares, compared to its average volume of 178,360. The firm has a market cap of $243.25 million, a P/E ratio of -1.82 and a beta of 0.41. CAMP4 Therapeutics has a 52-week low of $1.30 and a 52-week high of $7.75. The company's 50-day simple moving average is $4.63 and its 200 day simple moving average is $4.50.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last announced its quarterly earnings results on Thursday, March 5th. The Wireless communications provider reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.56). The business had revenue of $0.35 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 162.49% and a negative net margin of 2,298.54%. On average, research analysts forecast that CAMP4 Therapeutics will post -4.99 EPS for the current fiscal year.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.